[7]Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+ gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03. 2022 ASCO GI. Abstract 295. [8]NCCN Gastric Cancer. ...
2023年第25届ESMO世界胃道肠肿瘤大会(ESMO World GI 2023)将于2023年6月28日至7月1日在西班牙巴塞罗那举行,会议由欧洲肿瘤内科学会(ESMO)主办。ESMO世界消化道肿瘤大会是该领域首屈一指的全球性会议,会议内容包括影响胃肠道各组成部分的恶性肿瘤以及与胃肠癌患者护理相关的各个方面,包括筛查、诊断以及常见和罕见肿瘤...
[1]Abstract number 725MO,2023 ESMO. [2]Stelwagen J, de Vries EGE, Walenkamp AME. Current Treatment Strategies and Future Directions for Extrapulmonary Neuroendocrine Carcinomas: A Review. JAMA Oncol. 2021 Feb 25. doi: 10.100...
[7]Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+ gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DE...
[1] Do-Youn Oh, et al. 2022 ASCO GI. Abstract 378. [2] Alwu Ruth He et al, 2023 ESMO. 102P [3] Changhoon Yoo et al, 2023 ESMO, 97P [4] Hyehyun Jeong et al, 2023 ESMO, 104P [5] Yeonghak Bang, et al.2023ESMO 118P ...
2024年5月14号,和誉医药(港交所代码:02256)宣布,公司将在2024年ESMO GI大会上发布其自主研发的高选择性小分子FGFR4抑制剂依帕戈替尼 (Irpagratinib/ABSK011)与阿替利珠单抗联用治疗晚期肝细胞癌患者的最新临床试验数据。此次ESMO GI大会将于2024年6月26日至29日在德国慕尼黑举行。
[12] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2–positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01). 2022 ASCO GI Abstract. 242. ...
[1] Abstract number 725MO,2023 ESMO. [2] Stelwagen J, de Vries EGE, Walenkamp AME. Current Treatment Strategies and Future Directions for Extrapulmonary Neuroendocrine Carcinomas: A Review. JAMA Oncol. 2021 Feb 25. doi: 10.1001/jamaoncol.2020.8072. Epub ahead of print. PMID: 33630040. ...
[4].Markus HM, et al. RATIONALE-305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC). 2023 ASCO GI, Abstract#286. ...
2023 ASCO GI. Abstract LBA292.[8]Xu Rh, Shitara K, Ajani JA, Zolbetuximab + CAPOX in 1L claudin-18.2+ (CLDN18.2+)/HER2− locally advanced (LA) or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary phase 3 results from GLOW. 2023 ASCO GI. Abstract 4057...